Autolus Therapeutics plc — Q3 2023 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2023. Amounts below are in U.S. dollars; financial statement figures are unaudited. Autolus is a clinical-stage cell-therapy company developing programmed T-cell treatments for cancer and autoimmune diseases. It has no approved products and has generated no commercial product sales.
Financial performance and liquidity
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| License revenue | $0.4m | $2.4m | $1.7m | $2.4m |
| Research and development expense | $37.2m | $37.6m | $105.3m | $109.8m |
| General and administrative expense | $10.6m | $8.2m | $31.0m | $24.5m |
| Net loss | $45.8m | $42.8m | $131.2m | $121.9m |
| Net loss per ordinary share | $0.26 | $0.47 | $0.75 | $1.34 |
| Net cash used in operating activities | — | — | $120.8m | $97.7m |
- At September 30, 2023, cash and cash equivalents were $256.4m, down from $382.4m at December 31, 2022. Total assets were $406.1m and shareholders’ equity was $180.5m.
- Cash, cash equivalents and restricted cash decreased by $125.9m over the first nine months. Investing cash outflow was $9.5m, primarily property and equipment purchases; financing cash outflow was $0.9m.
- The company reported no debt outstanding subject to variable interest rates. Separately, its Blackstone collaboration liability for future royalties and sales milestones was $140.8m, up from $125.9m at year-end, including $14.9m of accrued interest expense in the nine-month period. Operating lease liabilities totaled about $52.5m.
- Gross margin is not applicable to product sales in this period because there were no commercial product sales. The filing does not provide a meaningful product-sales margin.
Changes versus the prior comparable period
- Nine-month net loss increased by $9.3m. Lower R&D spending and higher interest income were more than offset by increased G&A, disposal and impairment charges, higher Blackstone-related interest expense, and a lower income-tax benefit.
- Nine-month R&D expense fell $4.5m, mainly as clinical and manufacturing costs for obe-cel declined; higher staffing, facilities and information-technology costs, including costs associated with The Nucleus, partially offset the reduction.
- Nine-month G&A expense rose $6.5m, including higher personnel and commercial-readiness costs. The company also recorded a $3.8m loss on disposal of property and equipment and a $0.4m lease-asset impairment, neither recorded in the comparable 2022 period.
- License revenue was lower than in 2022, when Moderna exercised an option generating most of the prior-period revenue. 2023 revenue included a $1.2m Cabaletta license fee and milestone-related revenue from a Syncona portfolio investee.
Outlook, management commentary and risks
- Management stated that September 30 cash and cash equivalents were expected to fund current and planned operations and capital expenditures for at least 12 months from the financial statements’ issuance date. The company expects continued operating losses and says additional capital will be needed before it can generate sufficient product revenue; actual funding needs may exceed its estimates.
- At the time of the filing, management expected to submit the U.S. obe-cel BLA by year-end 2023 and an EU marketing authorization application in the first half of 2024. It also expected to start a Phase 1 study of obe-cel in refractory SLE in early 2024, with initial data expected in late 2024. These are forward-looking expectations, not reported outcomes.
- The Nucleus, a 70,000-square-foot U.K. manufacturing facility, had completed process performance qualification and was described as on track to support the obe-cel BLA. Estimated capacity was approximately 2,000 batches annually, which management expected to be sufficient for adult ALL demand in the U.S. and EU.
- Key risks include clinical and regulatory uncertainty, manufacturing scale-up and execution, competition, intellectual-property protection, reliance on third parties, and the possibility of needing additional financing on unfavorable terms or not obtaining it. Further equity financing could dilute shareholders. The company also cited foreign-exchange exposure and increasing compliance costs from voluntarily using U.S. domestic issuer reporting forms; it expected to lose emerging-growth-company status after December 31, 2023.
- No material legal proceedings or material changes to previously disclosed risk factors were reported, apart from the added reporting-compliance risks. Disclosure controls were assessed as effective, with no material change to internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether obe-cel’s regulatory submissions and review proceed on the timelines and terms described, and whether clinical results support approval.
- Cash burn, available financing runway and any financing or collaboration transactions; the stated runway depends on assumptions and does not assure funding beyond the stated period.
- Progress, utilization, costs and commercial readiness of The Nucleus, including whether estimated manufacturing capacity is achievable.
- Changes in the Blackstone royalty and milestone liability, including its assumptions, future payment burden and effect on interest expense.
- Lease commitments, including the 20-year Nucleus lease, and the financial impact of expanded U.S. reporting and loss of emerging-growth-company exemptions.